Event date
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.